173 related articles for article (PubMed ID: 22547820)
1. Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry.
Platt EJ; Gomes MM; Kabat D
Proc Natl Acad Sci U S A; 2012 May; 109(20):7829-34. PubMed ID: 22547820
[TBL] [Abstract][Full Text] [Related]
2. An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies.
Luallen RJ; Lin J; Fu H; Cai KK; Agrawal C; Mboudjeka I; Lee FH; Montefiori D; Smith DF; Doms RW; Geng Y
J Virol; 2008 Jul; 82(13):6447-57. PubMed ID: 18434410
[TBL] [Abstract][Full Text] [Related]
3. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.
Doores KJ; Fulton Z; Huber M; Wilson IA; Burton DR
J Virol; 2010 Oct; 84(20):10690-9. PubMed ID: 20702629
[TBL] [Abstract][Full Text] [Related]
4. Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity.
Drummer HE; Hill MK; Maerz AL; Wood S; Ramsland PA; Mak J; Poumbourios P
PLoS Pathog; 2013; 9(4):e1003218. PubMed ID: 23592978
[TBL] [Abstract][Full Text] [Related]
5. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
Scanlan CN; Pantophlet R; Wormald MR; Ollmann Saphire E; Stanfield R; Wilson IA; Katinger H; Dwek RA; Rudd PM; Burton DR
J Virol; 2002 Jul; 76(14):7306-21. PubMed ID: 12072529
[TBL] [Abstract][Full Text] [Related]
6. A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN.
Luallen RJ; Fu H; Agrawal-Gamse C; Mboudjeka I; Huang W; Lee FH; Wang LX; Doms RW; Geng Y
J Virol; 2009 May; 83(10):4861-70. PubMed ID: 19264785
[TBL] [Abstract][Full Text] [Related]
7. Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans.
Agrawal-Gamse C; Luallen RJ; Liu B; Fu H; Lee FH; Geng Y; Doms RW
J Virol; 2011 Jan; 85(1):470-80. PubMed ID: 20962094
[TBL] [Abstract][Full Text] [Related]
8. Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc.
Yang Q; Li C; Wei Y; Huang W; Wang LX
Bioconjug Chem; 2010 May; 21(5):875-83. PubMed ID: 20369886
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12.
Duenas-Decamp MJ; Clapham PR
J Virol; 2010 Sep; 84(18):9608-12. PubMed ID: 20610714
[TBL] [Abstract][Full Text] [Related]
10. Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.
Dutta M; Liu J; Roux KH; Taylor KA
J Virol; 2014 Nov; 88(21):12265-75. PubMed ID: 25122783
[TBL] [Abstract][Full Text] [Related]
11. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope.
Hoorelbeke B; Huskens D; Férir G; François KO; Takahashi A; Van Laethem K; Schols D; Tanaka H; Balzarini J
Antimicrob Agents Chemother; 2010 Aug; 54(8):3287-301. PubMed ID: 20498311
[TBL] [Abstract][Full Text] [Related]
12. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120.
Astronomo RD; Lee HK; Scanlan CN; Pantophlet R; Huang CY; Wilson IA; Blixt O; Dwek RA; Wong CH; Burton DR
J Virol; 2008 Jul; 82(13):6359-68. PubMed ID: 18434393
[TBL] [Abstract][Full Text] [Related]
13. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
[TBL] [Abstract][Full Text] [Related]
14. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.
Sanders RW; Venturi M; Schiffner L; Kalyanaraman R; Katinger H; Lloyd KO; Kwong PD; Moore JP
J Virol; 2002 Jul; 76(14):7293-305. PubMed ID: 12072528
[TBL] [Abstract][Full Text] [Related]
15. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
[TBL] [Abstract][Full Text] [Related]
16. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
McCaffrey RA; Saunders C; Hensel M; Stamatatos L
J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
[TBL] [Abstract][Full Text] [Related]
17. The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.
Chaillon A; Braibant M; Moreau T; Thenin S; Moreau A; Autran B; Barin F
J Virol; 2011 Apr; 85(7):3642-8. PubMed ID: 21248038
[TBL] [Abstract][Full Text] [Related]
18. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.
Huskens D; Van Laethem K; Vermeire K; Balzarini J; Schols D
Virology; 2007 Apr; 360(2):294-304. PubMed ID: 17123566
[TBL] [Abstract][Full Text] [Related]
19. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
Trkola A; Purtscher M; Muster T; Ballaun C; Buchacher A; Sullivan N; Srinivasan K; Sodroski J; Moore JP; Katinger H
J Virol; 1996 Feb; 70(2):1100-8. PubMed ID: 8551569
[TBL] [Abstract][Full Text] [Related]
20. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.
Gray ES; Moore PL; Pantophlet RA; Morris L
J Virol; 2007 Oct; 81(19):10769-76. PubMed ID: 17634239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
